Completed PHASE2 INTERVENTIONAL 7-arm NCT04278924

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia

Sponsor: Takeda

Conditions Primary Immune Thrombocytopenia

Interventions Placebo TAK-079

Updated 22 times since 2020 Last updated: May 28, 2025 Started: Nov 9, 2020 Primary completion: Apr 29, 2024 Completion: Apr 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Primary Immune Thrombocytopenia and is currently completed. Takeda leads this study, which shows 22 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

22 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Jul 2025 — Sep 2025 [monthly]

Completed PHASE2
Nov 2024 — Jul 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 17 earlier versions

Feb 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
May 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Nov 2022 — May 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
May 2022 — Jul 2022 [monthly]

Recruiting PHASE2
Oct 2021 — May 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE2
Sep 2020 — Nov 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE2
May 2020 — Jun 2020 [monthly]

Not Yet Recruiting PHASE2
Mar 2020 — May 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Barcelona, Spain , Berlin, Germany , Bologna, Italy , Boston, United States , Burgos, Spain , Catania, Italy , Charlottesville, United States , Dnipro, Ukraine , Frankfurt am Main, Germany and 35 more locations